JLE

Epileptic Disorders

MENU

Use of perampanel in children with refractory epilepsy of genetic aetiology Volume 24, issue 4, August 2022

Figure 1.

The pathogenic or likely pathogenic mutations in children with refractory epilepsy who received perampanel treatment.

Figure 2.

Response to perampanel after three, six and nine months in patients with childhood refractory epilepsy of genetic aetiology.

Figure 3.

Response to perampanel in patients with childhood refractory epilepsy with pathogenic or likely pathogenic genetic mutations (≥two patients/mutation) at three, six and nine months of follow-up.

Figure 4.

Adverse events (AE) during perampanel treatment showing the types of AEs and number of affected patients (A), and perampanel dose when the AEs initially occurred (B).